Clinical Trials Logo

Clinical Trial Summary

This Pilot study will enable development & assessment of a Polycystic Liver Disease-specific patient reported outcomes questionnaire (PLD-Q). Polycystic liver disease (PLD) is characterized by the formation of numerous cysts in the liver, and can lead to severe symptomatic hepatomegaly. It is common in patients with autosomal dominant polycystic liver disease (ADPLD) and autosomal dominant polycystic kidney disease (ADPKD).


Clinical Trial Description

As liver function is preserved, quality of life is the main outcome in PLD. Patient reported outcomes are increasingly utilized to assess treatment efficacy & can include any endpoint derived from patient reports & are usually assessed by questionnaire. Several existing generic questionnaires assess gastrointestinal symptoms, but include irrelevant items for polycystic liver disease (PLD) & do not examine relevant extra-abdominal symptoms. Also, a questionnaire that assesses the full range of PLD related problems is more likely to be responsive to changes after treatment initiation. Therefore, a tool that accurately detects changes in PLD symptoms is required. The development and first steps of validation of this questionnaire are already completed in Netherlands. We will further develop this questionnaire for English speaking patients and validate it in Mayo Clinic cohorts. The study contains three phases. Phase 1: pilot testing of the directly translated questionnaire (from dutch into english) in a small group of polycystic liver disease (PLD) patients. We will include both symptomatic & asymptomatic patients (i.e. from mild to severe PLD). Phase 2: further refinement of the questionnaire using the results of the pilot test and input of Mayo patient and clinician focus groups. Phase 3: Further validation in a large cohort of 200 PLD patients with (1) comparison with 200 controls without PLD, (2) cross-sectional correlation with total liver (TLV) & kidney volumes (TKV), (3) comparing ADPKD patients with & without PLD (5) against other validated questionnaires (e.g. SF36) & (5) development of a custom "Worry Questionnaire" examining disease-related worries & concerns. Finally, longitudinal analyses will be performed to assess PLD-Q sensitivity to change in symptoms. Statistical & psychometric analyses will be provided by Mayo Clinic quality of life Research group, & developed in accordance with Food and Drug Administration (FDA) guidance on patient-reported outcome measures in consultation with their Study Endpoints & Labeling Development Division. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02173080
Study type Observational
Source Mayo Clinic
Contact Marie C Hogan, MD, PhD
Phone 507-266-1963
Email Hogan.marie@mayo.edu
Status Recruiting
Phase
Start date June 2014
Completion date July 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05215964 - The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Recruiting NCT05500157 - Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts N/A
Completed NCT01354405 - Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) N/A
Completed NCT01315795 - Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease Phase 2/Phase 3
Active, not recruiting NCT05281328 - A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD Phase 2/Phase 3
Completed NCT01157858 - Everolimus and LongActing Octreotide Trial in Polycystic Livers Phase 2
Recruiting NCT05478083 - A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Phase 2
Recruiting NCT04645251 - Polycystic Liver Disease Registry (UK)
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Terminated NCT00934791 - Polycystic Liver Disease in Kidney Transplant N/A
Completed NCT02021110 - Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease Phase 2
Completed NCT01670110 - Pasireotide LAR in Severe Polycystic Liver Disease Phase 2
Active, not recruiting NCT00771888 - Open-Label Extension of LOCKCYST Trial Phase 2/Phase 3
Recruiting NCT03960710 - Automatic Segmentation of Polycystic Liver